ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: At the 3-month follow-up, a molecular reassessment of the BCR-ABL gene confirmed the absence of leukemic gene mutations or abnormalities, indicating a stable CML profile under semaglutide therapy.